Methionine Adenosyltransferase (MAT)

3-TYP is a SIRT3 inhibitor.

PF-9366 is a human methionine adenosyltransferase 2A (Mat2A) inhibitor, with an IC50 of 420 nM and a Kd of 170 nM.

MAT2A inhibitor 2 is a methionine adenosyltransferase 2A (MAT2A) inhibitor.

MAT2A inhibitor 1 is a methionine adenosyltransferase 2A (MATA2) inhibitor with an IC50 less than l00 nM.

AGI-24512 is a methionine adenosyltransferase 2A (MATA2 ) inhibitors useful for treatment of cancer. AGI-24512 blocks growth of MTAP-deleted cancer cells in vitro.

AGI-25696 is a methionine adenosyltransferase 2A (MATA2 ) inhibitors useful for treatment of cancer. AGI-25696 blocks growth of MTAP-deleted tumors in vivo.

FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM.

AG-270 is a first-in-class, reversible, and orally active methionine adenosyltransferase 2A (MAT2A) inhibitor. It functions as an allosteric and noncompetitive inhibitor, with an IC₅₀ of 14 nM. AG-270 is being explored for its therapeutic potential in cancers with MTAP deletions, where MAT2A inhibition leads to selective antitumor effects via disruption of methylation-dependent processes.

IDE397 (GSK-4362676) is a potent and selective inhibitor of methionine adenosyltransferase 2A (MAT2A). It exhibits strong anti-tumor activity, particularly in patient-derived xenograft (PDX) models with MTAP (methylthioadenosine phosphorylase) deletion. By targeting MAT2A in MTAP-deficient tumors, IDE397 exploits a synthetic lethality approach, making it a promising candidate for precision oncology research.